Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Sequential CD19 and CD22 CART for relapsed and refractory B cell ALL: Phase I results

View Full Paper
Ask AI
Bookmark
Share

Authors

CBChristina BaggottCMCesar E. MendozaRTRamya Tunuguntla

Discussion

Loading...

Member takes

Overview

Phase I clinical trial examines sequential CD19 and CD22 CAR-T efficacy in relapsed/refractory B-ALL, suggesting promising safety outcomes.

Key Points

  • All patients achieved flow and NGS remission after tisa-cel infusion, showing high efficacy in this sequential treatment approach.
  • In the cohort of six patients, three had detectable disease prior to treatment, indicating a challenging baseline for intervention.
  • CART therapy demonstrated acceptable safety, with only one incident of Grade 3 immune effector cell-associated neurotoxicity and manageable cytokine release syndrome.
  • This study underscores the feasibility of administering CD22 CAR T cells within 42 days after tisa-cel infusion, with positive signs of prolonged B cell aplasia.

Cite This Study

Baggott et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236ddadhttps://doi.org/10.1182/blood-2025-2374
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CD19/CD22 bispecific CAR-t cell therapy for relapsed/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial2025 · 2 citations
  2. 2Human CART22.19 Therapy in Refractory Pediatric B-ALL: Insights from a Named-Patient Cohort2025
  3. 3Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-t alone in relapsed/refractory large B-cell lymphoma2025
  4. 4Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma2025
  5. 5Tandem CD19/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r/r B-ALL2025 · 11 citations